title: [The use of Curosurf with premature infants--the prevention or treatment of the neonatal RDS].
abstract: A randomized clinical prospective study is carried out aiming to compare prophylaxis with Curosurf versus rescue treatment. 28 inborn VLBW I are included: 17 received Curosurf as prophylaxis and 11 controls, who received rescue treatment if indicated. Both groups are similar regarding mean body weight, mean gestational age, dosage of Curosurf, etc. Results underwent statistic analysis. Data from the study shows better effect from prophylaxis with Curosurf: smaller number of babies developed RDS and especially RDS grade III-IV (subsequently less babies needed a second dose of Curosurf); higher PaO2/FiO2 ratio; reduced duration of artificial ventilation and of oxygen therapy; reduced incidence of BPD. Results do not show statistically significant difference, but a tendency for ft. As a conclusion: prophylaxis with Curosurf leads to a decrease in the incidence and severity of RDS and to reduced duration of ventilation support and oxygen therapy.
authors: N
authors: N
authors: Iarŭkova
authors: T
authors: T
authors: Chernev
authors: A
authors: A
authors: Nikolov
mesh_terms: D001688:Biological Products; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy / Q000517:prevention & control*; D019102:Infant, Very Low Birth Weight; D010102:Oxygen Inhalation Therapy; D010743:Phospholipids; D011446:Prospective Studies; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa